CML Publications March 2025
As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications from low- and middle-income countries.
Clinical publications
Twin pregnancy during treatment with asciminib for chronic myeloid leukemia – a care report
Gutierrez de Moraes Pereira GBBM. Ann Hematol, March 2025
(epub ahead of print)
open access publication
Nilotinib induced diabetes in Japanese patients with chronic myeloid leukemia
Iwamoto Y et al. Intern Med, March 2025
open access publication
Severe acute cutaneous-only graft-versus-host disease after late relapse of chronic myeloid leukemia and ultraviolet B photography
Beeler JS et al. Haematologica, March 2025
open access publication
Alternative routes of drug administration: Exposure of imatinib using different formulations
Fiebrich-Westra HB et al. Cancer Chemother Pharmacol, March 2025
Evaluation of leukemic stem cell (CD26+) in chronic myeloid leukemia patients with different molecular response and in treatment-free remission
Camado MF et al. Clin Exp Med, March 2025
open access publication
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway
Wang J et al. Nat Cancer, March 2025 (epub ahead of print)
Scientific publications
PTBP2 promotes cell survival and autophagy in chronic myeloid leukemia by stabilizing BNIP3
Barik B et al. Cell Death Dis, March 2025
open access publication
Different in vitro models of chronic myeloid leukemia show different characteristics: Biological replicates are not biologically equivalent
Cavalleri A et al. Cell Biol Int, March 2025 (epub ahead of print)
open access publication
Comprehensive analysis of tyrosine kinase inhibitor domain mutations and imatinib resistance in chronic myeloid leukemia patients
Dhangar S et al. Leuk Res, March 2025 (epub ahead of print)
Selective translational control by PABPC1 phase separation regulates blast crisis and therapy resistance in chronic myeloid leukemia
Sun C et al. Nat Cell Biol, March 2025 (epub ahead of print)
Asciminib: The tyrosine kinase inhibitor with a unique mode of action - Review
Jain AG and Cortes JE. Expert Opin Pharmacother, March 2025 (epub ahead of print)
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: Does dose matter?
Dalgetty M and Cortes JE. Blood, March 2025 (epub ahead of print)
Imatinib and the dawn of precision cancer medicine
Druker BJ. Nat Med, March 2025
Living, not just surviving with CML – quality of life to the front of the line
Lipton JH and Rea D. Leukemia, March 2025 (epub ahead of print)
Chronic myeloid leukemia: A review
Jabbour E and Kantarjian H. JAMA, March 2025 (epub ahead of print)
Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors
Rodrigues Moreira P et al. J Oncol Pharm Pract, March 2025 (epub ahead of print)
Do we need another TKI for chronic myeloid leukemia?
Hjorth-Hansen H. Lancet Haematol, March 2025
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study
Busque L et al. Blood Cancer J, March 2025
open access publication
Pediatric CML publications
Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era
Yoshikawa T et al. Int J Hematol, March 2025 (epub ahead of print)
open access publication
Therapeutic drug monitoring of imatinib in pediatric chronic myeloid leukemia: Data from a real-world setting
Suttorp M et al. Br J Haematol, March 2025 (epub ahead of print)
open access publication
Management of children and adolescents with chronic myeloid leukemia in chronic-phase: International pediatric chronic myeloid leukemia expert panel recommendations
Millot F et al. Leukemia, March 2025 (epub ahead of print)
LMIC publications
The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukemia patient cohort
Kenmogne VL et al. Sci Rep, March 2025
open access publication